Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Frequently asked questions
What sector does Pharnext SA (ALPHA) operate in?
Pharnext SA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Pharnext SA (ALPHA) current stock price?
As of the latest data, Pharnext SA stock price is €0.00, with a previous close of €0.00.
What is Pharnext SA (ALPHA) current market capitalization?
Pharnext SA market cap is approximately 2.64 thousand.
What is Pharnext SA (ALPHA) Earnings Per Share (EPS)?
The trailing EPS is -€200.00.
Does Pharnext SA (ALPHA) pay dividends?
No. Pharnext SA does not pay a dividend.
What is Pharnext SA (ALPHA) beta (volatility) score?
Pharnext SA has a beta of -310.118, indicating lower volatility than the overall market.
